FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III

Abstract

FOXP3 interacts closely with immune biomarkers on tumor-infiltrating cells in TME. This study highlighted the crucial prognostic value and promising clinical applications of FOXP3 in SCLC.